ClinicalTrials.gov
ClinicalTrials.gov Menu

Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01785875
Recruitment Status : Completed
First Posted : February 7, 2013
Results First Posted : March 27, 2017
Last Update Posted : March 27, 2017
Sponsor:
Information provided by (Responsible Party):
Amgen

Brief Summary:
This study is designed to describe the long-term safety and efficacy of etelcalcetide (AMG 416) for the treatment of SHPT in adults with CKD on hemodialysis.

Condition or disease Intervention/treatment Phase
Hyperparathyroidism, Secondary Drug: Etelcalcetide Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 891 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter Single-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Study Start Date : July 2013
Actual Primary Completion Date : July 2015
Actual Study Completion Date : July 2015

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Etelcalcetide
Participants received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.
Drug: Etelcalcetide
Administered by bolus injection into the venous line of the dialysis circuit at the end of hemodialysis treatment, and prior to or during rinse-back with each hemodialysis session (ie, 3 times per week).
Other Name: AMG 416




Primary Outcome Measures :
  1. Number of Participants With Adverse Events (AEs) [ Time Frame: From first dose until 30 days after last dose; the treatment period was 52 weeks. ]
    Treatment-related adverse events are those the investigator indicated as having a reasonable possibility of having been caused by etelcalcetide. A serious adverse event is defined as an adverse event that meets at least 1 of the following serious criteria: • fatal • life threatening • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • congenital anomaly/birth defect • other medically important serious event.

  2. Number of Participants With Shift in Laboratory Values From Baseline Grade 0 or 1 to Post-baseline Grade 3 or 4 [ Time Frame: 52 weeks ]
    Laboratory toxicity grading was based on Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, where Grade 0 represents values in the normal range and grade 4 represents values with life-threatening consequences and urgent intervention indicated.

  3. Number of Participants Who Developed Anti-etelcalcetide Antibodies [ Time Frame: Baseline, Week 12, Week 24, Week 36, Week 53, the 30-day follow-up visit ]
    A validated dual flow-cell biosensor immunoassay was used to detect antibodies capable of binding etelcalcetide. The number of participants with a negative or no result at baseline and positive binding antibodies at any time post-baseline is reported.

  4. Change From Baseline in Blood Pressure [ Time Frame: Baseline and Weeks 24 and 48 ]
    Blood pressure (BP) values were taken post-hemodialysis assessments.


Secondary Outcome Measures :
  1. Percentage of Participants With > 30% Reduction From Baseline in PTH During the Efficacy Assessment Phase [ Time Frame: Baseline and the efficacy assessment phase, defined as the last 6 weeks prior to ending treatment for participants who completed a minimum of 8 weeks of treatment (weeks 46-52 for participants who completed 52 weeks of treatment) ]
    The efficacy assessment phase (EAP) is defined as the last 6 weeks before ending treatment, which was only for participants who completed a minimum of 8 weeks of treatment with etelcalcetide. If multiple assessments were available during the EAP, values were averaged.

  2. Percentage of Participants With > 30% Reduction From Baseline in PTH During the EAP12 [ Time Frame: Baseline and the efficacy assessment phase at month 12 (weeks 46-53) ]
    The efficacy assessment phase at 12 months (EAP12) was defined as the period from week 46 to 53 (inclusive). If multiple assessments were available during the EAP12, values were averaged.

  3. Percentage of Participants With PTH ≤ 300 pg/mL During the EAP [ Time Frame: Baseline and the efficacy assessment phase ]
  4. Percentage of Participants With PTH ≤ 300 pg/mL During the EAP12 [ Time Frame: Week 46 to 53 ]
  5. Percent Change From Baseline in Mean PTH During the EAP [ Time Frame: Baseline and the efficacy assessment phase ]
  6. Percent Change From Baseline in Mean PTH During the EAP12 [ Time Frame: Baseline and the efficacy assessment phase at month 12 (weeks 46-53) ]
  7. Percent Change From Baseline in Mean Corrected Calcium During the EAP [ Time Frame: Baseline and the efficacy assessment phase ]
  8. Percent Change From Baseline in Mean Corrected Calcium During the EAP12 [ Time Frame: Baseline and the efficacy assessment phase at month 12 (weeks 46-53) ]
  9. Percent Change From Baseline in Mean Corrected Calcium Phosphorus Product During the EAP [ Time Frame: Baseline and the efficacy assessment phase ]
  10. Percent Change From Baseline in Mean Corrected Calcium Phosphorus Product During the EAP12 [ Time Frame: Baseline and the efficacy assessment phase at month 12 (weeks 46-53) ]
  11. Percent Change From Baseline in Mean Phosphorus During the EAP [ Time Frame: Baseline and the efficacy assessment phase ]
  12. Percent Change From Baseline in Mean Phosphorus During the EAP12 [ Time Frame: Baseline and the efficacy assessment phase at month 12 (weeks 46-53) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject understands the study procedures and agrees to participate in the study by giving written informed consent.
  • Subject must complete the treatment and follow-up period, or have been discontinued for rising intact parathyroid hormone (iPTH), from an AMG 416 phase 3 parent study prior to the start of dosing in this study: 20120229 (NCT01785849), 20120230 (NCT01788046), or 20120359 (NCT01932970).
  • Subject agrees to not participate in another study of an investigational agent during the study.
  • Other Inclusion Criteria may apply

Exclusion Criteria:

  • Currently receiving treatment in another investigational device or drug study.
  • Currently receiving other investigational procedures while participating in this study.
  • Subject has known sensitivity to any of the products or components to be administered during dosing.
  • Subject has an unstable medical condition based on medical history, physical examination, and routine laboratory tests, or is otherwise unstable in the judgment of the Investigator.

Other Exclusion Criteria may apply


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01785875


  Hide Study Locations
Locations
United States, Alabama
Research Site
Birmingham, Alabama, United States, 35211
United States, Arkansas
Research Site
Pine Bluff, Arkansas, United States, 71603
United States, California
Research Site
Azusa, California, United States, 91702
Research Site
Bakersfield, California, United States, 93308
Research Site
Chula Vista, California, United States, 91910
Research Site
Cudahy, California, United States, 90201
Research Site
Fairfield, California, United States, 94534
Research Site
Glendale, California, United States, 91205
Research Site
Los Angeles, California, United States, 90022
Research Site
Los Angeles, California, United States, 90025
Research Site
Los Angeles, California, United States, 90048
Research Site
Lynwood, California, United States, 90262
Research Site
Northridge, California, United States, 91324
Research Site
Norwalk, California, United States, 90650
Research Site
Ontario, California, United States, 91762
Research Site
Riverside, California, United States, 92501
Research Site
San Gabriel, California, United States, 91776
Research Site
Simi Valley, California, United States, 93065
Research Site
Whittier, California, United States, 90603
United States, Colorado
Research Site
Arvada, Colorado, United States, 80002
Research Site
Denver, Colorado, United States, 80230
United States, Connecticut
Research Site
Stamford, Connecticut, United States, 06902
United States, Florida
Research Site
Coral Springs, Florida, United States, 33071
Research Site
Lauderdale Lakes, Florida, United States, 33313
Research Site
Miami, Florida, United States, 33150
Research Site
Miami, Florida, United States, 33173
Research Site
Ocala, Florida, United States, 34471
Research Site
Pembroke Pines, Florida, United States, 33025
Research Site
Pinecrest, Florida, United States, 33156
Research Site
Tampa, Florida, United States, 33614
United States, Georgia
Research Site
Augusta, Georgia, United States, 30901
Research Site
Macon, Georgia, United States, 31217
United States, Idaho
Research Site
Meridian, Idaho, United States, 83642
United States, Illinois
Research Site
Evanston, Illinois, United States, 60201
Research Site
Gurnee, Illinois, United States, 60031
United States, Indiana
Research Site
Merrillville, Indiana, United States, 46410
Research Site
Michigan City, Indiana, United States, 46360
United States, Kansas
Research Site
Wichita, Kansas, United States, 67214-2998
United States, Louisiana
Research Site
Baton Rouge, Louisiana, United States, 70808
Research Site
Lafayette, Louisiana, United States, 70503
Research Site
Shreveport, Louisiana, United States, 71101
United States, Massachusetts
Research Site
Springfield, Massachusetts, United States, 01107
United States, Michigan
Research Site
Detroit, Michigan, United States, 48202
Research Site
Detroit, Michigan, United States, 48236
Research Site
Kalamazoo, Michigan, United States, 49007
Research Site
Pontiac, Michigan, United States, 48341
United States, Mississippi
Research Site
Brookhaven, Mississippi, United States, 39601
Research Site
Columbus, Mississippi, United States, 39705
Research Site
Gulfport, Mississippi, United States, 39501
Research Site
Tupelo, Mississippi, United States, 38801
United States, Missouri
Research Site
Kansas City, Missouri, United States, 64111
Research Site
St. Louis, Missouri, United States, 63136
United States, Nebraska
Research Site
Lincoln, Nebraska, United States, 68510
United States, Nevada
Research Site
Las Vegas, Nevada, United States, 89106
Research Site
Reno, Nevada, United States, 89511
United States, New Hampshire
Research Site
Portsmouth, New Hampshire, United States, 03801
United States, New Jersey
Research Site
Eatontown, New Jersey, United States, 07724
United States, New York
Research Site
Bronx, New York, United States, 10461
Research Site
Brooklyn, New York, United States, 11212
Research Site
Brooklyn, New York, United States, 11235
Research Site
Great Neck, New York, United States, 11021
Research Site
Orchard Park, New York, United States, 14127
Research Site
Ridgewood, New York, United States, 11385
Research Site
Rosedale, New York, United States, 11422
Research Site
Yonkers, New York, United States, 10704
United States, North Carolina
Research Site
Carrboro, North Carolina, United States, 27510
Research Site
Charlotte, North Carolina, United States, 28207
Research Site
Durham, North Carolina, United States, 27704
Research Site
New Bern, North Carolina, United States, 28562
United States, Ohio
Research Site
Cincinnati, Ohio, United States, 45206
United States, Oklahoma
Research Site
Oklahoma City, Oklahoma, United States, 73116
United States, Pennsylvania
Research Site
Bethlehem, Pennsylvania, United States, 18017
Research Site
Philadelphia, Pennsylvania, United States, 19106
Research Site
Philadelphia, Pennsylvania, United States, 19118
United States, South Carolina
Research Site
Columbia, South Carolina, United States, 29203
Research Site
Orangeburg, South Carolina, United States, 29118
United States, Tennessee
Research Site
Chattanooga, Tennessee, United States, 37408
Research Site
Columbia, Tennessee, United States, 38401
Research Site
Knoxville, Tennessee, United States, 37923
Research Site
Nashville, Tennessee, United States, 37205
United States, Texas
Research Site
Arlington, Texas, United States, 76015
Research Site
Austin, Texas, United States, 78758
Research Site
Edinburg, Texas, United States, 78539
Research Site
Fort Worth, Texas, United States, 76105
Research Site
Fort Worth, Texas, United States, 76164
Research Site
Forth Worth, Texas, United States, 76104
Research Site
Grand Prairie, Texas, United States, 75050
Research Site
Houston, Texas, United States, 77004
Research Site
Houston, Texas, United States, 77054
Research Site
Lubbock, Texas, United States, 79430
Research Site
Mansfield, Texas, United States, 76063
Research Site
San Antonio, Texas, United States, 78205
Research Site
San Antonio, Texas, United States, 78215
Research Site
San Antonio, Texas, United States, 78229
United States, Virginia
Research Site
Alexandria, Virginia, United States, 22304
Research Site
Alexandria, Virginia, United States, 22306
Research Site
Fairfax, Virginia, United States, 22033
Research Site
Hampton, Virginia, United States, 23666
Research Site
Mechanicsville, Virginia, United States, 23116
Research Site
Norfolk, Virginia, United States, 23502
United States, West Virginia
Research Site
Bluefield, West Virginia, United States, 24701
Australia, New South Wales
Research Site
Liverpool, New South Wales, Australia, 2170
Research Site
St Leonards, New South Wales, Australia, 2065
Research Site
Westmead, New South Wales, Australia, 2145
Australia, Queensland
Research Site
Brisbane, Queensland, Australia, 4102
Australia, South Australia
Research Site
Adelaide, South Australia, Australia, 5000
Australia, Victoria
Research Site
Clayton, Victoria, Australia, 3168
Research Site
Parkville, Victoria, Australia, 3050
Austria
Research Site
Graz, Austria, 8036
Research Site
Linz, Austria, 4010
Research Site
Wien, Austria, 1090
Belgium
Research Site
Aalst, Belgium, 9300
Research Site
Baudour, Belgium, 7331
Research Site
Bonheiden, Belgium, 2820
Research Site
Brussels, Belgium, 1200
Research Site
Brussel, Belgium, 1090
Research Site
Bruxelles, Belgium, 1020
Research Site
Leuven, Belgium, 3000
Research Site
Liege, Belgium, 4000
Research Site
Liège, Belgium, 4000
Research Site
Roeselare, Belgium, 8800
Research Site
Tournai, Belgium, 7500
Canada, Alberta
Research Site
Edmonton, Alberta, Canada, T6G 2B7
Canada, Ontario
Research Site
Brampton, Ontario, Canada, L6R 3J7
Canada, Quebec
Research Site
Greenfield Park, Quebec, Canada, J4V 2H1
Research Site
Montreal, Quebec, Canada, H1T 2M4
Research Site
Montreal, Quebec, Canada, H4J 1C5
Czech Republic
Research Site
Hradec Kralove, Czech Republic, 500 05
Research Site
Novy Jicin, Czech Republic, 741 01
Research Site
Plzen, Czech Republic, 301 00
Research Site
Praha 4 - Nusle, Czech Republic, 140 00
Research Site
Praha 4, Czech Republic, 140 21
Research Site
Praha 6, Czech Republic, 169 00
Research Site
Slavkov u Brna, Czech Republic, 684 01
Research Site
Usti nad Orlici, Czech Republic, 562 18
France
Research Site
Bordeaux Cedex, France, 33076
Research Site
Caen, France, 14000
Research Site
La Tronche cedex, France, 38701
Research Site
Marseille cedex 5, France, 13385
Research Site
Marseille, France, 13253
Research Site
Poitiers, France, 86021
Research Site
Reims Cedex, France, 51092
Research Site
Saint-Ouen, France, 93400
Germany
Research Site
Berlin, Germany, 12053
Research Site
Dresden, Germany, 01307
Research Site
Erfurt, Germany, 99089
Research Site
Villingen-Schwenningen, Germany, 78052
Hungary
Research Site
Baja, Hungary, 6500
Research Site
Budapest, Hungary, 1037
Research Site
Budapest, Hungary, 1076
Research Site
Budapest, Hungary, 1106
Research Site
Esztergom, Hungary, 2500
Research Site
Gyor, Hungary, 9023
Research Site
Kaposvar, Hungary, 7400
Research Site
Kecskemet, Hungary, 6000
Research Site
Miskolc, Hungary, 3526
Research Site
Pecs, Hungary, 7624
Research Site
Zalaegerszeg, Hungary, 8900
Israel
Research Site
Ashkelon, Israel, 78278
Research Site
Jerusalem, Israel, 91120
Research Site
Kfar-Saba, Israel, 44281
Research Site
Nahariya, Israel, 22100
Research Site
Tel Aviv, Israel, 64239
Research Site
Tel Hashomer, Israel, 52621
Research Site
Zerifin, Israel, 70300
Italy
Research Site
Ancona, Italy, 60131
Research Site
Lecco, Italy, 23900
Research Site
Milano, Italy, 20122
Research Site
Milano, Italy, 20142
Research Site
Pavia, Italy, 27100
Research Site
Verona, Italy, 37126
Netherlands
Research Site
Amsterdam, Netherlands, 1081 HV
Research Site
Enschede, Netherlands, 7511 JX
Research Site
Rotterdam, Netherlands, 3079 DZ
Research Site
Venlo, Netherlands, 5912 BL
Poland
Research Site
Bialystok, Poland, 15-540
Research Site
Gdansk, Poland, 80-952
Research Site
Golub-Dobrzyn, Poland, 87-400
Research Site
Krakow, Poland, 31-501
Research Site
Lodz, Poland, 90-153
Research Site
Rybnik, Poland, 44-200
Research Site
Warszawa, Poland, 02-006
Research Site
Warszawa, Poland, 02-097
Research Site
Warszawa, Poland, 04-749
Research Site
Zamosc, Poland, 87-100
Russian Federation
Research Site
Moscow, Russian Federation, 123183
Research Site
Saint Petersburg, Russian Federation, 191104
Research Site
Saint Petersburg, Russian Federation, 196247
Research Site
Saint Petersburg, Russian Federation, 197110
Research Site
Saint Petersburg, Russian Federation, 198510
Research Site
Saint-Petersburg, Russian Federation, 195067
Research Site
Saint-Petersburg, Russian Federation, 195257
Research Site
Yaroslavl, Russian Federation, 150062
Spain
Research Site
Cordoba, Andalucía, Spain, 14004
Research Site
Santander, Cantabria, Spain, 39008
Research Site
Barcelona, Cataluña, Spain, 08003
Research Site
Barcelona, Cataluña, Spain, 08025
Research Site
Barcelona, Cataluña, Spain, 08035
Research Site
Barcelona, Cataluña, Spain, 08036
Research Site
Majadahonda, Madrid, Spain, 28222
Research Site
Madrid, Spain, 28041
Sweden
Research Site
Karlstad, Sweden, 651 85
Research Site
Stockholm, Sweden, 141 86
Research Site
Uppsala, Sweden, 751 85
United Kingdom
Research Site
Cambridge, United Kingdom, CB2 2QQ
Research Site
Coventry, United Kingdom, CV2 2DX
Research Site
London, United Kingdom, NW3 2QG
Research Site
Nottingham, United Kingdom, NG5 1PB
Research Site
Sheffield, United Kingdom, S5 7AU
Sponsors and Collaborators
Amgen
Investigators
Study Director: MD Amgen

Additional Information:
Responsible Party: Amgen
ClinicalTrials.gov Identifier: NCT01785875     History of Changes
Other Study ID Numbers: 20120231
KAI-4169-008 ( Other Identifier: KAI Pharmaceuticals, Inc (wholly owned subsidiary of Amgen Inc.) )
2012-002808-41 ( EudraCT Number )
First Posted: February 7, 2013    Key Record Dates
Results First Posted: March 27, 2017
Last Update Posted: March 27, 2017
Last Verified: August 2016

Keywords provided by Amgen:
Secondary Hyperparathyroidism (SHPT), chronic kidney disease (CKD), hemodialysis, parathyroid hormone (PTH), hypocalcemia, bone and mineral metabolism

Additional relevant MeSH terms:
Kidney Diseases
Neoplasm Metastasis
Renal Insufficiency, Chronic
Hyperparathyroidism
Hyperparathyroidism, Secondary
Urologic Diseases
Neoplastic Processes
Neoplasms
Pathologic Processes
Renal Insufficiency
Parathyroid Diseases
Endocrine System Diseases